Aligos Therapeutics, Inc.
General ticker "ALGS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $103.1M (TTM average)
Aligos Therapeutics, Inc. follows the US Stock Market performance with the rate: 10.9%.
Estimated limits based on current volatility of 4.3%: low 9.34$, high 10.17$
Factors to consider:
- Total employees count: 70 (+6.1%) as of 2024
- Top business risk factors: Operational and conduct risks, Pandemic risks, Product development delays, Labor/talent shortage/retention, Commercialization challenges
- Current price 20.9% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [12.75$, 43.77$]
- 2025-12-31 to 2026-12-31 estimated range: [7.02$, 25.77$]
Financial Metrics affecting the ALGS estimates:
- Negative: with PPE of -3.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -32.75 <= 0.33
- Negative: Shareholder equity ratio, % of -41.33 <= 18.93
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ALGS quotes
Long-term ALGS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $13.91MM | $15.53MM | $3.94MM |
| Operating Expenses | $111.49MM | $103.66MM | $93.10MM |
| Operating Income | $-97.58MM | $-88.13MM | $-89.15MM |
| Non-Operating Income | $1.64MM | $1.24MM | $-41.73MM |
| R&D Expense | $85.08MM | $73.04MM | $70.27MM |
| Income(Loss) | $-95.94MM | $-86.88MM | $-130.88MM |
| Taxes | $0.11MM | $0.80MM | $0.33MM |
| Profit(Loss)* | $-96.05MM | $-87.68MM | $-131.21MM |
| Stockholders Equity | $103.90MM | $92.08MM | $-28.97MM |
| Assets | $146.69MM | $151.53MM | $70.09MM |
| Operating Cash Flow | $-79.39MM | $-79.00MM | $-80.74MM |
| Capital expenditure | $0.94MM | $0.02MM | $0.13MM |
| Investing Cash Flow | $-26.29MM | $44.98MM | $-18.28MM |
| Financing Cash Flow | $0.16MM | $88.33MM | $0.35MM |
| Earnings Per Share** | $-2.25 | $-3.52 | $-20.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.